Targeting TMEM205 mediated drug resistance in ovarian clear cell carcinoma using oncolytic virus

BACKGROUND: Ovarian clear cell carcinoma (OCCC) accounts for approximately 8–10% of epithelial ovarian cancers in the United States. Although it is rare, OCCC usually presents with treatment challenges and the overall prognosis is far worse than high grade serous ovarian cancer HGSOC. The objective...

Descripción completa

Detalles Bibliográficos
Autores principales: Saini, Uksha, Smith, Brentley Q., Dorayappan, Kalpana Deepa Priya, Yoo, Ji Young, Maxwell, G. Larry, Kaur, Balveen, Konishi, Ikuo, O’Malley, David, Cohn, David E., Selvendiran, Karuppaiyah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9730683/
https://www.ncbi.nlm.nih.gov/pubmed/36476493
http://dx.doi.org/10.1186/s13048-022-01054-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9730683/
https://www.ncbi.nlm.nih.gov/pubmed/36476493
http://dx.doi.org/10.1186/s13048-022-01054-5

Ejemplares similares